Habteyes Hailu Tola1, Khalid Jamal Khadoura2, Worku Jimma3, Saharnaz Nedjat4, Reza Majdzadeh5. 1. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University Medical, Tehran, Iran; Tuberculosis/HIV Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia. Electronic address: habtetola@gmail.com. 2. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University Medical, Tehran, Iran; Departiment of Internal Medicine, Shifa Complex Hospital, Gaza, Palestine. Electronic address: k.khadourah@gmail.com. 3. Department of Information Science, College of Natural Sciences, Jimma University, Jimma, Ethiopia. Electronic address: worku.jimma@yahoo.com. 4. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University Medical, Tehran, Iran; Knowledge Utilization Research Center, Tehran University Medical Sciences, Tehran, Iran. Electronic address: saharnaznedjat@gmail.com. 5. Department of Epidemiology and Biostatistics, School of Public Health, Tehran University Medical, Tehran, Iran; Knowledge Utilization Research Center, Tehran University Medical Sciences, Tehran, Iran. Electronic address: rezamajd@tums.ac.ir.
Abstract
BACKGROUND: We aimed to compare and contrast the proportions of treatment outcome between developing and developed countries in children treated for multidrug resistance tuberculosis (MDR-TB). METHODS: We conducted a systematic review and meta-analysis of articles published on children treated for MDR-TB. We searched published articles from electronic databases: PubMed/Medline, EMBASE, Scopus and Web of Science for English articles without restricting publication year. We employed random-effects meta-analysis model to estimate the pooled proportions of treatment success, death, treatment failure and lost to follow up. RESULTS: We pooled data of 1,343 children obtained from 17 included studies, and the overall pooled treatment success was 77.0% (95% Confidence Interval (CI), 69.0-85.0). Pooled treatment success in developing countries was 73.0% (63.0-83.0), while in developed countries 87.0% (81.0-94.0). The overall pooled treatment failure was 3.0% (1.0-6.0), while death 8.0% (4.0-11.0) and lost to follow up 10.0% (6.0-4). CONCLUSION: MDR-TB treatment success in children is well achieved in both developed and developing countries by currently available drugs. Improving MDR-TB treatment programme is vital to achieve the maximum treatment successful. Promoting research on pediatric MDR-TB treatment outcome could also help to fill evidence gap.
BACKGROUND: We aimed to compare and contrast the proportions of treatment outcome between developing and developed countries in children treated for multidrug resistance tuberculosis (MDR-TB). METHODS: We conducted a systematic review and meta-analysis of articles published on children treated for MDR-TB. We searched published articles from electronic databases: PubMed/Medline, EMBASE, Scopus and Web of Science for English articles without restricting publication year. We employed random-effects meta-analysis model to estimate the pooled proportions of treatment success, death, treatment failure and lost to follow up. RESULTS: We pooled data of 1,343 children obtained from 17 included studies, and the overall pooled treatment success was 77.0% (95% Confidence Interval (CI), 69.0-85.0). Pooled treatment success in developing countries was 73.0% (63.0-83.0), while in developed countries 87.0% (81.0-94.0). The overall pooled treatment failure was 3.0% (1.0-6.0), while death 8.0% (4.0-11.0) and lost to follow up 10.0% (6.0-4). CONCLUSION: MDR-TB treatment success in children is well achieved in both developed and developing countries by currently available drugs. Improving MDR-TB treatment programme is vital to achieve the maximum treatment successful. Promoting research on pediatric MDR-TB treatment outcome could also help to fill evidence gap.
Authors: Mahmoud Tareq Abdelwahab; Sean Wasserman; James C M Brust; Keertan Dheda; Lubbe Wiesner; Neel R Gandhi; Robin M Warren; Frederick A Sirgel; Graeme Meintjes; Gary Maartens; Paolo Denti Journal: Antimicrob Agents Chemother Date: 2021-09-20 Impact factor: 5.191
Authors: Kefyalew Addis Alene; Megan B Murray; Brittney J van de Water; Mercedes C Becerra; Kendalem Asmare Atalell; Mark P Nicol; Archie C A Clements Journal: JAMA Netw Open Date: 2022-06-01